Sign In
Buy COLL
$31.06
+0.580 (+1.90%)
At Close: Jun 03, 2026
Q2 2020 EPS Estimates for Collegium Pharmaceutical Inc Cut by Analyst (NASDAQ:COLL)
07:54am, Saturday, 25'th Apr 2020
Collegium Pharmaceutical Inc (NASDAQ:COLL) – Analysts at William Blair decreased their Q2 2020 earnings estimates for shares of Collegium Pharmaceutical in a research note issued to investors on Tue
Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Zogenix (ZGNX)
04:06pm, Friday, 24'th Apr 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (BIIB) and Zogenix (ZGNX). Biogen (BIIB) In a report issued on
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (NASDAQ: BIIB) and Zogenix (NASDAQ: ZGNX)
04:06pm, Friday, 24'th Apr 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (
BIIB
–
Research Report
) and Zogenix (
ZGNX
–
Research Report
).
Biogen (BIIB)
In a report issued on Apri
Collegium Pharmaceutical (COLL) Gets a Buy Rating from Needham
12:28pm, Friday, 24'th Apr 2020
Needham analyst Serge Belanger assigned a Buy rating to Collegium Pharmaceutical (COLL) today and set a price target of $38.00. The company's shares
Collegium Pharmaceutical (COLL) Gets a Buy Rating from Needham
12:28pm, Friday, 24'th Apr 2020
Needham analyst Serge Belanger assigned a Buy rating to Collegium Pharmaceutical (COLL – Research Report) today and set a price
Collegium Pharmaceutical Inc (NASDAQ:COLL) Expected to Post Q1 2020 Earnings of $0.08 Per Share
06:04am, Friday, 24'th Apr 2020
Collegium Pharmaceutical Inc (NASDAQ:COLL) – Investment analysts at William Blair reduced their Q1 2020 earnings per share estimates for shares of Collegium Pharmaceutical in a note issued to invest
Collegium to Host Conference Call to Discuss First Quarter 2020 Financial Results and Provide Corporate Update
08:01pm, Thursday, 23'rd Apr 2020
STOUGHTON, Mass., April 23, 2020 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on.
SCYNEXIS (SCYX) Receives a Buy from H.C. Wainwright
11:25am, Wednesday, 22'nd Apr 2020
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on SCYNEXIS (SCYX), with a price target of $3.50. The company's
SCYNEXIS (SCYX) Receives a Buy from H.C. Wainwright
11:25am, Wednesday, 22'nd Apr 2020
In a report released today,
Oren Livnat
from H.C. Wainwright reiterated a
Buy
rating on SCYNEXIS (
SCYX
–
Research Report
), with a price target of
$3.50
. The company’s shares closed last Tuesday
Cara Therapeutics (CARA) Gets a Buy Rating from H.C. Wainwright
03:43pm, Tuesday, 21'st Apr 2020
H.C. Wainwright analyst Oren Livnat maintained a Buy rating on Cara Therapeutics (CARA) today and set a price target of $33.00. The company's shares
Cara Therapeutics (CARA) Gets a Buy Rating from H.C. Wainwright
03:43pm, Tuesday, 21'st Apr 2020
H.C. Wainwright analyst Oren Livnat maintained a Buy rating on Cara Therapeutics (CARA – Research Report) today and set a
Should You Buy This Biotech That Makes A Lower Risk Painkiller?
10:20am, Tuesday, 21'st Apr 2020
A company making abuse-deterrent opioids and that's barely listed in any nation-wide opioid litigation is becoming a rising star despite the prescription overdose crisis.
Collegium Pharmaceutical Inc (NASDAQ:COLL) Expected to Announce Quarterly Sales of $77.45 Million
08:50am, Tuesday, 21'st Apr 2020
Analysts expect that Collegium Pharmaceutical Inc (NASDAQ:COLL) will post $77.45 million in sales for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Collegium Phar
Collegium Pharmaceutical Inc (NASDAQ:COLL) Short Interest Update
09:10am, Sunday, 19'th Apr 2020
Collegium Pharmaceutical Inc (NASDAQ:COLL) was the recipient of a large decrease in short interest during the month of March. As of March 31st, there was short interest totalling 4,650,000 shares, a d
1,668 Shares in Collegium Pharmaceutical Inc (NASDAQ:COLL) Acquired by Ballast Advisors LLC
10:04am, Saturday, 18'th Apr 2020
Ballast Advisors LLC purchased a new position in Collegium Pharmaceutical Inc (NASDAQ:COLL) during the first quarter, according to the company in its most recent disclosure with the Securities and Exc
